Page 162 - Read Online

Page 8 of 9 Yang et al. Hepatoma Res 2019;5:13 I http://dx.doi.org/10.20517/2394-5079.2019.04

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin
Gastroenterol 2010;44:239-45.
2. Ferlay J, Shin HR,Bray F, Forman D, Mathers C, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J
Cancer 2010;127:2893-917.
3. Yuen MF, Chan AO, Wong BC, Hui CK, Ooi GC, et al. Transarterial chemoembolization for inoperable, early stage hepatocellular
carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. Am J Gastroenterol
2003;98:1181-5.
4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves
survival. Hepatology 2003;37:429-42.
5. Marelli L, Shusang V, Buscombe JR, Cholongitas E, Stigliano R, et al. Transarterial injection of (131)I-lipiodol, compared with
chemoembolization, in the treatment of unresectable hepatocellular cancer. J Nucl Med 2009;50:871-7.
6. Kim KM, Kim JH, Park IS, Ko GY, Yoon HK, et al. Reappraisal of repeated transarterial chemoembolization in the treatment of
hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol 2009;24:806-14.
7. Peng ZW, Zhang YJ, Liang HH, Lin XJ, Guo RP, et al. Recurrent hepatocellular carcinoma treated with sequential transcatheter
arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology 2012;262:689-700.
8. Zhao M, Wang JP, Li W, Huang ZL, Zhang FJ, et al. Comparison of safety and efficacy for transcatheter arterial chemoembolization
alone and plus radiofrequency ablation in the treatment of single branch portal vein tumor thrombus of hepatocellular carcinoma and
their prognosis factors. Zhonghua Yi Xue Za Zhi 2011;91:1167-72.
9. Kim JW, Kim JH, Won HJ, Shin YM, Yoon HK, et al. Hepatocellular carcinomas 2-3 cm in diameter: transarterialchemoembolization
plus radiofrequency ablation vs. radiofrequency ablation alone. Eur J Radiol 2012;81:189-93.
10. Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, et al. Small hepatocellular carcinoma: is radiofrequency ablation combined
with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology
2009;252:905-13.
11. Dong YS, Zhang ZY, Yang XG. Clinical efficacy of transcatheter arterial chemoembolization combined with radiofrequency ablation
for large hepatocellular carcinoma. Chinese Journal of General Surgery 2013;16:486-88.
12. Du XQ. Analysis of the efficacy of transcatheter arterial chemoembolization combined with radiofrequency ablation in the treatment
of primary large liver cancer. Clinical Medical Research and Practice 2017;2:15-16.
13. Ge MG, Zhang W. TACE and RFA sequential treatment of 88 cases of advanced liver cancer. Chinese Medical Innovation 2009;6:29.
14. Kuang YL, Wang Z, Yang ZL, Tan ZM. Analysis of short-term efficacy of transcatheter arterial chemoembolization combined with
radiofrequency ablation for advanced primary liver cancer. Journal of Hepatobiliary and Pancreatic Surgery 2017;29:363-7.
15. Li T, Jia KD, Zhang KQ. Therapeutic effect of transcatheter arterial chemoembolization combined with ultrasound-guided
radiofrequency ablation for large hepatocellular carcinoma. Anhui Medicine 2013;17:1709-11.
16. Liang MH. Hepatic arterial chemoembolization combined with multipolar radiofrequency ablation for the treatment of large liver
cancer. Chinese Journal of Gerontology 2011;31:2862-64.
17. Liu M, Yang SF, Wang HL, Gu P, Huang WK. Analysis of the efficacy and prognosis of transcatheter arterial chemoembolization
(TACE) combined with percutaneous radiofrequency ablation (RFA) in the treatment of advanced hepatocellular carcinoma. Journal
of Practical Cancer 2015.
18. Shen L, Chen MH, Yan K, Yang W, Gao W. To investigate the clinical application of percutaneous radiofrequency ablation combined
with hepatic arterial chemoembolization in the treatment of large hepatocellular carcinoma. Chinese Journal of Ultrasound Imaging
2004.
19. Song Y, Jiang SF, Long HY, Zhang YQ. Clinical study of hepatic arterial chemoembolization combined with percutaneous
radiofrequency ablation for the treatment of large hepatocellular carcinoma. Advances in Modern and General Surgery 2008;11:203-7.
20. Zhang XB, Wang X, Zheng YH, Zhang XJ. Clinical study of sequential hepatic arterial chemoembolization combined with
radiofrequency ablation for large hepatocellular carcinoma. Chinese Journal of Physicians 2016.
21. Yang P, Liang M, Zhang Y, Shen B. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC.
Adv Ther 2008;25:787-94.
22. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, et al. The Cochrane Collaboration’s tool for assessing risk of bias in
randomised trials. BMJ 2011;343:d5928.
23. Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, et al. Radiofrequency ablation with or without transcatheter arterial
chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013;31:426-32.